Long-term Results of Zuma-1 Trial for Patients with NHL

Video

Frederick Locke, MD, co-leader of the Department of Blood and Marrow Transplant and Cellular Immunotherapy Program at Moffitt Cancer Center, discussed the long-term follow-up results of the pivotal ZUMA-1 trial. These updated findings were presented at the 2017 ASH Annual Meeting, showing promise in the treatment of patients with non-Hodgkin lymphoma.

Frederick Locke, MD, co-leader of the Department of Blood and Marrow Transplant and Cellular Immunotherapy Program at Moffitt Cancer Center, discussed the long-term follow-up results of the pivotal ZUMA-1 trial. These updated findings were presented at the 2017 ASH Annual Meeting, showing promise in the treatment of patients with non-Hodgkin lymphoma.

ZUMA-1 is a multicenter trial looking axicabtegene ciloleucel (Yescarta), also known as axi-cel, which is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The long-term results were presented after a median follow-up of 15.4 months looking at 108 patients from the phase I and II portions of the study.

Recent Videos
Related Content